Please assess the completion status of the following clinical trial:

Trial Title: Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~1. Phase Ib: Patient must have histologically or cytologically documented solid tumor malignancies.~   Phase II: Patients must have histologically or cytologically confirmed locally advanced, unresectable or metastatic carcinoma of the breast.~2. Patient is male or female and ≥18 years of age on the day of signing informed consent.~3. Patient must have performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale and life expectancy \> 3 months.~4. Patient must have evaluable disease. Measureable disease is not required~5. Patient must have adequate organ function~6. Female patient of childbearing potential must have a negative serum or urine pregnancy test quantitative human chorionic gonadotropin (β-hCG) within 72 hours prior to receiving the first dose of study medication and agree to the use of effective methods of contraception while on study.~7. Any number of prior lines of chemotherapy in the metastatic setting is allowed.~8. Concomitant use of bisphosphonates is allowed.~9. Patients with stable and clinically insignificant CNS disease are allowed. Patients must be off steroids with no new CNS symptoms or findings on radiographic imaging for 1 month.~10. Patients willing and able to complete the questionnaires.~11. Patients willing and able to comply with the study protocol for the duration of the study.~12. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.~EXCLUSION CRITERIA:~1. Patients who have had chemotherapy or radiotherapy within two weeks, 4 weeks for nitrosoureas, mitomycin C, pegylated-doxorubicin and one half-life for bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study Day 1.~2. If the patient has residual toxicity from prior treatment, toxicity must be ≤ Grade 1.~3. Patients with non-healing surgical wounds. Patients must be at least two weeks from a major surgical procedure, and surgical wounds must be completely healed.~4. Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for at least 1 month prior to entry as defined as:~   1. no evidence of new or enlarging CNS metastasis~  2. off steroids that are used to minimize surrounding brain edema. Patients with clinically insignificant brain metastases that do not require treatment are eligible.~5. Patients with known hypersensitivity to the components of study drug or its analogs.~6. Significant cardiovascular impairment:~   1. Congestive heart failure, Clinically significant cardiac arrhythmia, history or current evidence of a myocardial infarction during the last 6 months, and/or a current ECG tracing that is abnormal in the opinion of the treating Investigator, or unstable angina~  2. QTc prolongation \>480 msec (Bazett's Formula) or congenitally long QT syndrome (LQTS)~7. Severe/uncontrolled concurrent illness/infection~8. Patients with other active, current primary malignancies, other than carcinoma in situ of the cervix or non-melanoma skin cancer~9. Patients with \> Grade 1 neuropathy at screening~10. Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative~11. Patient is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study.~12. Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1b: 1.1 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort) (Type: EXPERIMENTAL): Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.1 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
- Phase 1b: 1.4 mg/m2 Eribulin Combination w/ Cyclophosphamide (Solid Tumor Escalation Cohort) (Type: EXPERIMENTAL): Dose escalation cohort will include all patients with solid tumors. Eribulin mesylate 1.4 mg/ m2 on days 1 and 8 followed by cyclophosphamide 600 mg/ m2 on day 1 of a 21-day cycle.The highest dose level at which no more than one of six subjects experience DLT defines the MTD
- Phase II: Eribulin Combination w/ Cyclophosphamide (Breast Cancer Expansion Cohort) (Type: EXPERIMENTAL): Dose-expansion cohort will enroll patients with advanced breast cancer only after Phase Ib enrollment has been concluded. The MTD of Eribulin mesylate will be administered on days 1 and 8 followed by cyclophosphamide 600 mg/m2 on day 1 of a 21-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).